For years, GLP-1 medications meant one thing: injections. Ozempic, Wegovy, Mounjaro, Zepbound — all delivered via subcutaneous injection pens. But 2026 has opened a new chapter. With Foundayo (orforglipron) and oral Wegovy (semaglutide tablets) now available, patients have genuine oral alternatives for weight management.
So which is better — a pill or an injection? The answer isn't as simple as "whichever you prefer." Let's break down the data.
The Current GLP-1 Landscape
Oral Options (Pills)
| Medication | Generic | Type | Dosing | FDA Indication |
|---|---|---|---|---|
| Foundayo | Orforglipron | GLP-1 agonist | Daily tablet | Weight management |
| Wegovy oral | Semaglutide | GLP-1 agonist | Daily tablet | Weight management |
| Rybelsus | Semaglutide | GLP-1 agonist | Daily tablet | Type 2 diabetes |
Injectable Options
| Medication | Generic | Type | Dosing | FDA Indication |
|---|---|---|---|---|
| Wegovy | Semaglutide | GLP-1 agonist | Weekly injection | Weight management |
| Wegovy HD | Semaglutide 7.2mg | GLP-1 agonist | Weekly injection | Weight management |
| Zepbound | Tirzepatide | GLP-1/GIP dual agonist | Weekly injection | Weight management |
| Ozempic | Semaglutide | GLP-1 agonist | Weekly injection | Type 2 diabetes |
| Mounjaro | Tirzepatide | GLP-1/GIP dual agonist | Weekly injection | Type 2 diabetes |
Weight Loss: The Numbers
Let's compare the headline weight loss figures from pivotal clinical trials. Important: always check whether numbers are ITT (treatment regimen/all randomized) or completers analysis. ITT is more conservative; completers reflects those who stayed on medication.
Injectable Weight Loss Results
- Zepbound (tirzepatide) 15mg: ~20.9% ITT / ~22.5% completers at 72 weeks (SURMOUNT-1)
- Wegovy HD (semaglutide) 7.2mg: ~21% completers at 72 weeks (STEP UP)
- Wegovy (semaglutide) 2.4mg: ~15% ITT / ~17% completers at 68 weeks (STEP 1)
- Ozempic (semaglutide) 2mg: ~15% in diabetes patients with obesity
Oral Weight Loss Results
- Wegovy oral (semaglutide) 25mg: ~16.6% completers at 64 weeks (OASIS 4)
- Foundayo (orforglipron) 17.2mg: ~11.2% ITT / ~12.4% completers at 72 weeks (ATTAIN-1)
- Rybelsus (semaglutide) 14mg: ~4–5% body weight loss (PIONEER trials, diabetes population)
What the Numbers Tell Us
Injectables still lead on raw weight loss. Zepbound at ~20.9% (ITT) and Wegovy HD at ~21% (completers) represent the current ceiling. Even standard Wegovy at ~15% (ITT) exceeds oral Foundayo's 11.2% (ITT). Oral Wegovy at ~16.6% (completers, OASIS 4) comes close to standard injectable Wegovy but requires strict fasting conditions.
However, raw trial numbers don't tell the whole story. Several factors narrow this gap in real-world practice:
The Adherence Factor
Clinical trials have excellent adherence because participants are closely monitored. Real-world data tells a different story:
- Injectable GLP-1 discontinuation at 12 months: 40–60% of patients stop within the first year (multiple real-world studies)
- Reasons for discontinuation: Cost, injection burden, side effects, supply issues
- Oral medication adherence: Generally 15–25% higher than injectable medications across therapeutic categories
A medication that loses 22.5% of body weight but gets discontinued at month 6 may produce worse real-world outcomes than a medication that loses 11.2% but is taken consistently for years. The best GLP-1 is the one you actually take.
Convenience Comparison
| Factor | Pills (Foundayo) | Injections (Wegovy/Zepbound) |
|---|---|---|
| Administration | Swallow a tablet | Subcutaneous injection |
| Frequency | Daily | Weekly |
| Needles | None | Required (pen needles) |
| Storage | Room temperature | Refrigerated (before first use) |
| Travel | Carry a pill bottle | Cold pack, needles, sharps container |
| Sharps disposal | N/A | Required |
| Injection site reactions | N/A | Possible (redness, itching) |
| Food restrictions | None (Foundayo); fasting required (oral Wegovy) | None |
Note: Oral Wegovy (semaglutide tablets) requires taking the tablet on an empty stomach with no more than 4 ounces of plain water, then waiting at least 30 minutes before eating, drinking, or taking other medications. Foundayo has no such restrictions — take it with or without food, with any amount of water.
Side Effect Profiles
All GLP-1 medications share similar GI side effects. The rates vary:
- Nausea: Foundayo (33.7%) > Oral Wegovy (~25%) > Injectable Wegovy (~20%) > Zepbound (~18%)
- Constipation: Foundayo (25.4%) > Zepbound (~12%) > Injectable Wegovy (~10%)
- Diarrhea: Foundayo (23.1%) > Injectable Wegovy (~10%) > Zepbound (~8%)
Oral formulations tend to have higher GI side effect rates, likely because of direct contact with the GI tract before absorption. These effects are typically transient and managed through slow titration.
Cost Comparison
- Foundayo: $149–$249/mo self-pay; $25/mo with savings card
- Oral Wegovy: ~$1,200/mo list; savings card available
- Injectable Wegovy: ~$1,349/mo list; savings card available
- Zepbound: ~$1,086/mo list; $499/mo via LillyDirect
Foundayo is the clear cost leader. Oral Wegovy, despite being a pill, carries a list price comparable to its injectable counterpart because the active ingredient (semaglutide) is still a peptide requiring expensive manufacturing.
What About Dual Agonists?
Zepbound and Mounjaro (tirzepatide) are GLP-1/GIP dual receptor agonists, which is why they achieve higher weight loss than single GLP-1 agonists. Currently, there is no oral dual agonist available, though several are in development. If maximum weight loss is the primary goal and cost/injection burden isn't a barrier, Zepbound remains the most potent option.
Who Should Choose What?
Choose a GLP-1 pill if:
- You have needle phobia or strong preference against injections
- You travel frequently and want hassle-free medication management
- Cost is a primary factor (especially Foundayo)
- You're starting GLP-1 therapy for the first time and want the easiest entry point
- You value room-temperature storage and simple logistics
Choose an injectable GLP-1 if:
- Maximum weight loss is your primary goal
- You prefer once-weekly dosing over daily
- You have good insurance coverage for injectables
- You've already tried and responded well to an injectable
- You're interested in dual-agonist therapy (Zepbound/Mounjaro)
The Future: Oral Dual Agonists
The pipeline is promising. Several companies are developing oral versions of dual and triple receptor agonists. As these reach the market, the efficacy gap between pills and injections will likely narrow further. For now, the choice between pill and injection is really a choice between convenience/cost (pills) and maximum efficacy (injections).
The Bottom Line
Injectable GLP-1s win on raw weight loss numbers. Oral GLP-1s win on convenience, accessibility, and (in Foundayo's case) cost. Neither is universally "better" — it depends entirely on what matters most to you. And remember: the most effective medication is the one you consistently take. A daily pill you never miss beats a weekly injection you skip half the time.
Sources
- Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)
- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021;384(11):989-1002. (STEP 1)
- Knop FK, et al. "Oral semaglutide 50 mg taken once daily in adults with overweight or obesity (OASIS 1)." Lancet. 2023;402(10403):705-719.
- Eli Lilly. ATTAIN-1 Phase 3 Trial Results. 2025.
- Novo Nordisk. STEP UP Trial Results. 2025.